Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$131.85

-0.75 (-0.57%)

15:13
07/17/17
07/17
15:13
07/17/17
15:13

Technical Earnings Preview: Johnson & Johnson trending down ahead of news

The shares have been in a minor downtrend since hitting a peak of price in late June. If the news or outlook are a negative disappointment, next support of note would be at the $130 area. A breakdown below $130 would confirm a larger topping process underway. Next supports below would be at $128.25, $127.51, the $125 area, and $122.50. If the news is instead a positive surprise, a breakout above the $133 area would break the downtrend. Next resistance levels to watch as potential upside objectives would be at $135.01 and the 52-week high at $137. A move above $137 would open up a run to the $140 area.

  • 18

    Jul

  • 09

    Aug

JNJ Johnson & Johnson
$131.85

-0.75 (-0.57%)

07/14/17
WELS
07/14/17
NO CHANGE
WELS
Underperform
J&J approval another negative for Valeant, says Wells Fargo
Wells Fargo analyst David Maris says Valeant Pharmaceuticals (VRX) has a new competitor in the psoriasis space after the FDA yesterday approved Tremfya from Johnson & Johnson (JNJ). The news is another negative for Valeant, which is about to launch its own psoriasis treatment, Siliq, in the second half of 2017, Maris tells investors in a research note. With Talz from Eli Lilly (LLY), Humira from AbbVie (ABBV), Cosentyx from Novartis (NVS) and now J&J as a new competitor, Valeant is unlikely to be competitive in the psoriasis market, Maris contends. He believes his peak sales estimate of $250M for Siliq may prove optimistic given the competition. Maris an Underperform rating on Valeant with a $9 price target. The drugmaker closed yesterday at $17.29.
06/27/17
06/27/17
NO CHANGE

Large cap pharma could benefit from upcoming executive order, says Wells Fargo
Wells Fargo says that, based on press reports, large cap pharma could benefit from President Trump's upcoming executive order on drug pricing. The firm says the articles indicate that the order will not create major reforms or do anything to lower consumers' costs or solve current pricing issues. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
06/20/17
ADAM
06/20/17
NO CHANGE
Target $10
ADAM
Buy
Novadaq competing bids possible if not probable, says Canaccord
Canaccord analyst Jason Mills noted Novadaq (NVDQ) received an acquisition offer from Stryker (SYK) at a much greater equity value than what the company was trading at prior to the bid. Although he thinks Stryker is the most logical buyer of the franchise, he thinks there are several other potential acquirers, including Medtronic (MDT), Johnson & Johnson (JNJ) and Intuitive Surgical (ISRG), in that order. Mills believes this is a good exit for the company and that Stryker is getting a good asset. Mills maintains his Buy rating and $10 price target on Novadaq shares.
06/14/17
RHCO
06/14/17
NO CHANGE
RHCO
Eli Lilly has positive read through from J&J data, says SunTrust
SunTrust analyst John Boris says that data for Johnson & Johnson's (JNJ) Invokana for diabetes represented a best-case scenario for Eli Lilly (LLY). J&J's drug "significantly reduced the combined risk of cardiovascular death, myocardial infarction and nonfatal stroke in diabetes patients at risk for or with a history of CV diseases," and its efficacy on CV death is positive for the SGLT-2 class, to which Eli Lilly's Jardiance also belongs, according to the analyst. But the data leaves Jardiance, which reduced CV death by a statistically significant 38% versus Invokana's non-significant 13%, as the best in the class, wrote the analyst, who reiterates a $101 price target and a Buy rating on Eli Lilly.

TODAY'S FREE FLY STORIES

GOOGL

Alphabet Class A

$969.03

-29.28 (-2.93%)

14:31
07/26/17
07/26
14:31
07/26/17
14:31
Recommendations
Alphabet Class A analyst commentary  »

Alphabet recent weakness…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOP

SPDR Oil Exploration and Production Fund

$32.95

0.32 (0.98%)

14:30
07/26/17
07/26
14:30
07/26/17
14:30
Options
Sizable spread in SPDR Oil Exploration and Production ETF »

Sizable spread in SPDR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:30
07/26/17
07/26
14:30
07/26/17
14:30
General news
FOMC takeaway: there was one subtle shift in the Fed's statement »

FOMC takeaway: there was…

YY

YY

$73.02

2.33 (3.30%)

14:25
07/26/17
07/26
14:25
07/26/17
14:25
Options
YY call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Aug

14:25
07/26/17
07/26
14:25
07/26/17
14:25
General news
FX Action: The dollar »

FX Action: The dollar…

14:20
07/26/17
07/26
14:20
07/26/17
14:20
General news
Treasury Action: yields whipsawed in the wake of the FOMC »

Treasury Action: yields…

ABX

Barrick Gold

$16.00

-0.04 (-0.25%)

14:20
07/26/17
07/26
14:20
07/26/17
14:20
Technical Analysis
Technical Earnings Preview: Barrick Gold range-bound before earnings »

Shares have been marking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

AMZN

Amazon.com

$1,039.87

0.92 (0.09%)

, ULTA

Ulta Beauty

$256.61

4.53 (1.80%)

14:18
07/26/17
07/26
14:18
07/26/17
14:18
Hot Stocks
Piper says Amazon not near-term threat to Ulta Beauty »

Shares of Ulta Beauty…

AMZN

Amazon.com

$1,039.87

0.92 (0.09%)

ULTA

Ulta Beauty

$256.61

4.53 (1.80%)

EL

Estee Lauder

$98.85

0.1 (0.10%)

FB

Facebook

$165.28

-0.72 (-0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 27

    Jul

  • 13

    Sep

WEC

WEC Energy

$62.56

0.38 (0.61%)

14:17
07/26/17
07/26
14:17
07/26/17
14:17
Earnings
WEC Energy sees Q3 EPS 63c-67c, consensus 72c »

Says guidance assumes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

$NYE

NYSE Market Internals

14:16
07/26/17
07/26
14:16
07/26/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:15
07/26/17
07/26
14:15
07/26/17
14:15
General news
FOMC held rates steady and gave no firm date on the balance sheet unwind »

FOMC held rates steady…

SQM

SQM

$39.35

0.31 (0.79%)

14:10
07/26/17
07/26
14:10
07/26/17
14:10
Options
Call buyers opening a notable new position in Chemical and Mining of Chile »

Call buyers opening a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

14:05
07/26/17
07/26
14:05
07/26/17
14:05
General news
Federal Reserve says inflation declined and running below 2% »

The Federal Reserve said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:05
07/26/17
07/26
14:05
07/26/17
14:05
General news
ECB's Nowotny agrees with Weidmann »

ECB's Nowotny agrees…

UMC

UMC

$2.45

-0.11 (-4.30%)

14:02
07/26/17
07/26
14:02
07/26/17
14:02
Downgrade
UMC rating change  »

UMC downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

14:02
07/26/17
07/26
14:02
07/26/17
14:02
General news
Fed says stance of monetary policy 'remains accommodative' »

The Federal Reserve said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

14:01
07/26/17
07/26
14:01
07/26/17
14:01
General news
Fed sees balance sheet normalization 'relatively soon' »

The Federal Reserve said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:01
07/26/17
07/26
14:01
07/26/17
14:01
General news
FOMC Meeting Announcement Federal Funds Rate data reported »

FOMC Meeting Announcement…

SPX

S&P 500

14:00
07/26/17
07/26
14:00
07/26/17
14:00
General news
Breaking General news story on S&P 500 »

Federal Reserve leaves…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RBS

RBS

$6.67

0.04 (0.60%)

13:58
07/26/17
07/26
13:58
07/26/17
13:58
Hot Stocks
RBS provides update on remaining State Aid obligation regarding Williams & Glyn »

Following the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UPS

UPS

$112.70

-0.52 (-0.46%)

, FDX

FedEx

$214.34

-0.03 (-0.01%)

13:50
07/26/17
07/26
13:50
07/26/17
13:50
Earnings
On The Fly: What to watch in UPS earnings report »

UPS (UPS) is scheduled to…

UPS

UPS

$112.70

-0.52 (-0.46%)

FDX

FedEx

$214.34

-0.03 (-0.01%)

BA

Boeing

$229.76

17.3 (8.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 27

    Jul

  • 07

    Aug

  • 21

    Aug

GG

Goldcorp

$13.56

0.14 (1.04%)

13:50
07/26/17
07/26
13:50
07/26/17
13:50
Options
Defensive option play in GoldCorp ahead of earnings »

Defensive option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

FCEL

FuelCell

$1.48

0.03 (2.07%)

13:50
07/26/17
07/26
13:50
07/26/17
13:50
Hot Stocks
Breaking Hot Stocks news story on FuelCell 

FuelCell trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$11.06

-0.215 (-1.91%)

13:48
07/26/17
07/26
13:48
07/26/17
13:48
Hot Stocks
Ford drops after quarterly beat attributed to tax credits »

Shares of car giant Ford…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 01

    Aug

FB

Facebook

$165.28

-0.72 (-0.43%)

13:45
07/26/17
07/26
13:45
07/26/17
13:45
Periodicals
Facebook TV episodes ready for Mid-August, Bloomberg reports »

Facebook has asked…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 13

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.